Tiffany Mayo, MD, FAAD

An expert discusses how successful atopic dermatitis management requires patient-centered care and shared decision-making, emphasizing that treatment selection should match disease impact rather than just body surface area, with both biologics and JAK inhibitors offering safe and effective options.

An expert discusses how patient preferences, particularly needle anxiety, must be balanced with treatment effectiveness, demonstrating that oral JAK inhibitors can be excellent alternatives for patients who cannot tolerate injectable biologics.

An expert discusses how a 55-year-old African American man’s case highlights challenges in diagnosing atopic dermatitis in skin of color, emphasizing the importance of recognizing different disease presentations and addressing postinflammatory hyperpigmentation concerns.

An expert discusses how a 5-year-old child with severe atopic dermatitis affecting sleep and school performance demonstrates the need for systemic therapy escalation, with dupilumab being an ideal choice given its efficacy for both atopic dermatitis and comorbid asthma.

An expert discusses how personalizing systemic atopic dermatitis treatment requires considering factors such as disease severity, patient impact, treatment failures, age, comorbidities, and patient preferences when selecting between biologics and JAK inhibitors.

An expert discusses how atopic dermatitis creates significant physical and quality-of-life burdens affecting up to 20% of pediatric and 10% of adult patients globally, with presentations varying across age groups and key unmet needs including improved access to care and disease recognition across different skin tones.